AET BioTech develops biosimilars along EMA standards for distribution in worldwide markets. Built on a 50 year success story of the oldest player in the field of generics, the AET Group (Alfred E. Tiefenbacher GmbH & Co. KG), AET BioTech benefits from exceptional experience in scientific, legal and technical fields and leverages its specific know-how in joint development programs, taking biosimilars from concept to registration and supplying to leading pharmaceutical brands.
Honoring the specific challenges inherent in the development of biologics on the one hand, and the exceptional economic opportunities of providing biological medications with the highest standards of quality at reasonable prices on the other hand, AET BioTech’s business model offers selected partners opportunities to safeguard access to regional distribution rights by early investment into a shared risk development model.
In addition to such shared risk development models, AET BioTech also offers its know-how to other biotech companies to enable them to access the European market with their biosimilar products.
AET BioTech welcomes parties interested in collaborating on any area of the business to make contact › here.